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Abstract
Background: Current magnetic resonance imaging (MRI) techniques for measuring extraocular muscle (EOM) volume
enlargement are not ideally suited for routine follow-up of Graves’ ophthalmopathy (GO) because the difficulty of
segmenting the muscles at the tendon insertion complicates and lengthens the study protocol.
Purpose: To measure the EOM sampled volume (SV) and assess its correlation with proptosis.
Material and Methods: A total of 37 patients with newly diagnosed GO underwent 3-T MRI scanning with iterative
decomposition of water and fat (IDEAL) sequences with and without contrast enhancement. In each patient, the three
largest contiguous coronal cross-sectional areas (CSA) on the EOM slices were segmented using a polygon selection tool
and then summed to compute the EOM-SV. Proptosis was evaluated with the Hertel index (HI). The relationships
between the HI value and EOM-SV and between HI and EOM-CSA were compared and assessed with Pearson’s cor-
relation coefficient and the univariate regression coefficient. Inter-observer and intra-observer variability were
calculated.
Results: HI showed a stronger correlation with EOM-SV (P< 0.001; r¼ 0.712, r2¼ 0.507) than with EOM-CSA
(P< 0.001; r¼ 0.645 and r2¼ 0.329). The intraclass correlation coefficient indicated that the inter-observer agreement
was high (0.998). The standard deviation between repeated measurements was 1.9–5.3%.
Conclusion: IDEAL sequences allow for the measurement EOM-SV both on non-contrast and contrast-enhanced scans.
EOM-SV predicts proptosis more accurately than does EOM-CSA. The measurement of EOM-SV is practical and
reproducible. EOM-SV changes of 3.5–8.3% can be assumed to reflect true volume changes.
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Introduction
Graves’ orbitopathy (GO) is the most common extra-
thyroidal manifestation of Graves’ disease (1).
Although it generally arises in patients with Graves’
hyperthyroidism, individuals with primary auto-
immune hypothyroidism and even those without a cur-
rent or previous history of thyroid dysfunction may
also be affected (2). The acute phase of GO is charac-
terized by edema and soft tissue congestion, the
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imbibition of intra-orbital fat, and enlarged extraocular
muscles (EOM). Pathological EOM enlargement
can induce proptosis, optic nerve compression,
diplopia, and medial orbital wall fracture and may
eventually require decompression surgery (3,4).
Identifying an early marker of EOM enlargement
would help predict future exophthalmos and related
complications.
The most common approach to evaluate EOM
enlargement is to measure the maximum cross-sectional
area of the muscles (EOM-CSA) on standard radio-
logical scans: the technique is easy to perform and
involves a short learning curve (5). EOM volume pro-
vides more information than that of the CSA and does
so on a wider section of the muscles (4–6); however,
current volume measurement techniques are time-con-
suming and involve complex assessments based on iso-
tropic sequences, which prevents their routine clinical
use.
The present MRI study describes a practical
approach to EOM volume measurement based on the
assumption that in GO patients, the pathological EOM
enlargement is mostly confined to the muscle belly and
spares the tendons, conferring a spindle-like shape (7).
The aims of the study were as follows: (i) to segment,
measure, and sum the EOM-CSA of the three largest
contiguous slices from the central portion of the EOM
to calculate the EOM-SV; (ii) to correlate the EOM-SV
with the severity of proptosis (Hertel index); (iii) to test
the reproducibility of EOM-SV measurements; and (iv)
to assess the usefulness of contrast enhancement in
EOM evaluation.
Material and Methods
Patients
This retrospective cohort study involved 50 consecutive
participants (13 men, 37 women; median
age¼ 47 10.7 years). Of these, 37 met the inclusion
criteria and were enrolled in the study. Patients were
included if they had newly diagnosed active GO treated
with antithyroid medications (methimazole). Patients
who had received immunosuppressive treatment with
steroids or orbital radiotherapy and surgical decom-
pression, those with known hypersensitivity to gadoli-
nium-based contrast agents, and those in whom
contrast agent use was contraindicated were excluded.
The diagnosis of active GO was made at the
Department of Ophthalmology of the authors’ institu-
tion based on a clinical activity score originally
described by Mourits et al. (8). All participants pro-
vided written informed consent to be included in the
study, which was in line with the principles of the
Declaration of Helsinki.
Image acquisition
Patients underwent high-field orbital scanning with
iterative decomposition of water and fat with echo
asymmetry and least-squares estimation (IDEAL)
sequences in a Discovery MR750 3.0-T system (GE
Healthcare, Milwaukee, WI, USA). They were
scanned with their eyes closed and fixed in the primary
position (gaze straight ahead). IDEAL fast spin-echo
(FSE) anisotropic sequences were acquired before and
after the administration of gadolinium (Gd; gadopen-
tetate dimeglumine 0.2mL/kg). IDEAL FSE
sequences and T1-weighted (T1W) and T2-weighted
(T2W) images (in-phase, out-of-phase, water, fat)
were obtained in the axial and coronal planes. The
MRI protocol included the following: a localizer
scan (39 s); a parallel-imaging calibration scan (6 s);
axial T2W IDEAL images (102 s); coronal T2W
IDEAL images (146 s); axial T1W IDEAL images
(83 s); and coronal T1W IDEAL images (118 s). The
protocol also involved the array spatial sensitivity-
encoding technique (ASSET; GE Healthcare) with
a slice acceleration factor of 1 and a phase acceler-
ation factor of 1.25 performed in the in-plane,
phase-encoding direction. The acquisition parameters
are reported in Table 1. The total scan time was
8min 23 s without enhancement and 9min 11 s with
contrast enhancement.
Image interpretation
Image assessment and segmentation were performed
independently by an experienced radiologist and two
radiology residents. Images were evaluated on a dedi-
cated workstation using INFINITT software
(INFINITT Co., Ltd., Seoul, Republic of Korea) and
ImageJ (NIH, Bethesda, MD, USA), a Java-
based image processing program (9). Proptosis was
assessed on axial IDEAL T2W in-phase and water
images by measuring the perpendicular distance
between the interzygomatic line and the apex of the
globe (Fig. 1); a value 22mm was considered patho-
logical (10). The non-contrast-enhanced EOM-SV was
obtained from coronal T1W IDEAL FSE fat
sequences, whereas the contrast-enhanced EOM-SV
was obtained from coronal T1W IDEAL FSE water
sequences.
EOM segmentation was performed using the ImageJ
polygon selection tool, which defines the EOM shape
through a series of line segments with the movable
points on the outline shown as small squares. Linear
interpolation between the points generates the complete
outline. The vertex points identifying a polygon were
traced manually and then moved to adapt the shape of
the polygon to the EOM shape. After segmentation,
measurement of the central coronal EOM slices allowed
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for the selection of the three sections with the largest
CSA, which corresponded to the central muscle por-
tion. The EOM-SV was obtained by adding together
these three areas from each muscle for each orbit; the
largest of the three CSAs was taken as the maximum
EOM-CSA (Figs. 2 and 3). The EOMs assessed in each
orbit were the medial, lateral, and inferior rectus; the
levator palpebrae and the superior rectus were assessed
together (superior rectus complex), as it was difficult to
separate them in the images.
Statistical analysis
The inter-observer variability of the measurements
obtained on IDEAL sequences was calculated with
the intraclass correlation coefficient (ICC) and 95%
confidence intervals (two-way mixed-effects model;
0¼ no agreement, 1¼ perfect agreement between
measurements).
Intra-observer variation was assessed using an image
subset from eight randomly selected patients, four for
non-contrast and four for contrast-enhanced scans.
These images, which included four EOM-SV (hence,
eight EOM-SV per patient), were re-evaluated twice
by each operator one year from the first assessment.
This image subset was therefore examined three times
and included 24 EOM-SV per patient (eight EOM-SV
measured at the time of the study and eight plus eight
measured after a year), i.e. a total number of 96 non-
contrast and 96 contrast-enhanced EOM-SV. The mean
EOM-SV and SD were calculated and expressed as
percentages.
The relationship between HI value and maximum
EOM-CSA measured on non-contrast and on con-
trast-enhanced images was determined and compared
with the relationship between HI value and non-con-
trast and contrast-enhanced EOM-SV using Pearson’s
correlation and univariate regression.
Data were analyzed with SPSS 19 (SPSS Inc.,
Chicago, IL, USA). A P value <0.05 was considered
significant.
Results
Correlation between HI and the EOM measures
A total of 1776 (888 non-contrast-enhanced and 888
contrast-enhanced) segmented coronal sections were
obtained from the 74 orbits and 592 EOM-SV (296
non-contrast-enhanced and 296 contrast-enhanced)
were calculated in each patient. The HI value signifi-
cantly correlated with all the EOM measures tested in
the study. The non-contrast images showed a weak cor-
relation with the maximum EOM-CSA (P< 0.001,
r¼ 0.389) and a moderately strong correlation with
the EOM-SV (P< 0.001, r¼ 0.574). Stronger correl-
ations were found in the contrast-enhanced images,
Table 1. MRI acquisition parameters.
Ax Cor AxþCE CORþCE
Matrix size (mm) 320 192 320 192 320 192 320 192
TR (ms) 2423 3039 287 425
TE (ms) 102 102 102 102
Slice thickness (mm) 4 4 4 4
ETL 15 15 15 15
NEX 1 1 1 1
FOV (mm) 200 200 200 200 200 200 200 200
Spacing (mm) 0 0 0 0
Echo bandwidth (Hz/px) 41.67 41.67 41.67 41.67
Ax, axial plane; Cor, coronal plane; AxþCE, axial plane with contrast enhancement; CorþCE, coronal plane with contrast enhancement; TR,
repetition time; TE, echo time; ETL, echo train length; NEX, number of excitations; FOV, field of view.
Fig. 1. Axial T2W IDEAL in-phase image of a 71-year-old
man with unilateral right proptosis evaluated with the Hertel
index (HI).
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where the HI value correlated strongly with the max-
imum EOM-CSA (P< 0.000, r¼ 0.645) and even more
strongly with the EOM-SV (P< 0.000, r¼ 0.712). These
data are reported in Table 2.
The univariate regression analysis, where HI was the
dependent variable and maximum contrast-enhanced
EOM-CSA and non-contrast EOM-SV were the inde-
pendent variables, showed a weak correlation
(r2¼ 0.329), whereas the correlation with contrast-
enhanced EOM-SV was moderately strong
(r2¼ 0.507). These data are also reported in Table 2.
A scatter plot showing a linear regression line between
proptosis and all the dimensional parameters deter-
mined in the study is reported in Fig. 4.
Inter-observer agreement
The ICC showed high inter-observer agreement
(Table 3): 0.997 for non-contrast images and 0.998 for
contrast-enhanced images.
Intra-observer variability
The measurements performed on the image subset from
eight randomly selected individuals showed a mean
EOM-SV of 127.2mm3 (range¼ 83–261mm3) with an
SD of 2.9% (range¼ 1.9–3.7%) in the 96 non-contrast-
enhanced images and a mean EOM-SV of 132.8mm3
(range¼ 88–236mm3) with an SD of 3.2%
Fig. 2. Pathological enlargement of the right medial rectus muscle studied with a non-contrast coronal T1W IDEAL fat sequence. The
maximum CSA (b) of the medial rectus (mr-CSA) measures 98.2 mm2; its addition to the area of the previous (a) and subsequent
(c) section provides the sampled volume of the medial rectus muscle: 276.4 mm3.
Fig. 3. Pathological enlargement of the left medial rectus muscle studied on contrast-enhanced coronal T1W IDEAL water
sequences. The maximum CSA (b) of the medial rectus (mr-CSA) measures 51.3 mm2; its addition to the area of the previous
(a) and subsequent (c) section provides the sampled volume of the medial rectus muscle: 138.2 mm3.
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Fig. 4. Scatter plot showing the linear regression lines between the HI and extraocular muscle sampled volume (EOM-SV, orange line)
and maximum EOM-CSA (green line). The correlation is stronger with non-contrast (b) and contrast-enhanced (d) EOM-SV than with
non-contrast (a) and contrast-enhanced (c) EOM-CSA. HI values are expressed in mm; EOM-CSA are expressed in mm2; EOM-SV are
expressed in mm3.
Table 2. Results of correlations.
bEOM-CSA bEOM-SV cEOM-CSA cEOM-SV
HI p 0.001 0.001 0.000 0.000
r 0.389 0.574 0.645 0.712
r2 0.184 0.329 0.329 0.507
HI, Hertel index; r, Pearson’s correlation coefficient; r2, coefficient of determination; bEOM-CSA, non-contrast-enhanced maximum cross-sectional
extraocular muscle area obtained with IDEAL fat sequences; bEOM-SV, non-contrast-enhanced extraocular muscle sampled volume obtained with
IDEAL fat sequences; cEOM-CSA, contrast-enhanced maximum cross-sectional extraocular muscle area obtained with IDEAL water sequences;
cEOM-SV, contrast-enhanced extraocular muscle sampled volume obtained with IDEAL water sequences.
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(range¼ 1.9–5.3%) in the 96 contrast-enhanced images.
When the values measured in these eight patients were
pooled, the mean EOM-SV was 130.08mm3
(range¼ 102–151mm3) and the SD was 3%
(range¼ 1.9–5.3%). These data are reported in Table 4.
Discussion
In this study, we performed the EOM-SV segmentation
and highlighted a significant correlation between HI
and both non-contrast and contrast-enhanced EOM-
SV. HI exhibited a stronger relationship with the
EOM-SV than with the EOM-CSA.
This is probably because a volume parameter (EOM-
SV) provided more comprehensive information than did
a measure of area (CSA). Indeed, the correlation between
HI and EOM also indirectly revealed the effect of the
EOM-SV and EOM-CSA on proptosis, because the
increased infra-orbital pressure determined by the EOM
enlargement results in protrusion of the globe. Since the
EOM-SV represented a broader area involved by the
pathological enlargement, it demonstrated spindle-like
EOM involvement and explained the increase in infra-
orbital pressure that results in proptosis more exhaust-
ively compared with a single coronal CSA. Our findings
agree with reports describing the involvement of an exten-
sive EOM portion in GO (10,11). However, neither the
correlation between HI and EOM-SV nor the regression
coefficients reached the maximum possible value.
Probably, this indicated that retro-orbital fat imbibition
and neo-adipogenesis contributed to proptosis (12–14).
The contrast-enhanced EOM-SV correlated better with
proptosis. This is likely because contrast enhancement
provided a more accurate assessment of the EOM and
of the rich vascularity and wide interstitial spaces that
are found, especially in the orbital layer (15).
In patients showing marked EOM-SV changes over
time, it is critical to determine whether the difference is
reliable (response/no response to therapy) or is opera-
tor-dependent. Since changes in volume falling within
the range of 2 SD of the mean would, by definition,
not be significantly different from the mean at a 5% level
of significance (16), a change >2 SD (4.9%) constituted
the lowest detectable significant difference by this tech-
nique. Consequently, if the EOM volume change com-
pared to a baseline examination exceeds 3.5–8.3%, it is
caused in 95% of cases by the disease or by treatment,
not by operator-dependent factors. Moreover, a diagno-
sis of pathological EOMenlargement based on a value in
excess of a cut-off is not reliable. In fact, there is
Table 4. Data from 96 non-contrast and 96 contrast-enhanced extraocular muscle sampled volumes (EOM-SV) estimated in 8
(4þ 4) randomly selected patients.
EOM-SV range (mm3) Mean EOM-SV (mm3) SD/mean (%) 2 SD (%)
Non-contrast-enhanced EOM-SV
MR 83–144 102.0 3.7 8.0
IR 105–261 177.4 3.3 4.0
LR 78–177 121.8 2.6 4.1
SRC 76–165 107.7 1.9 3.8
Average 127.2 2.9 5.0
Contrast-enhanced EOM-SV
MR 88–185 123.1 2.3 4.0
IR 79–221 130.1 1.9 3.8
LR 96–144 126.2 5.3 8.3
SRC 96–236 151.8 3.2 3.5
Average 132.8 3.2 4.9
Non-contrast-enhancedþ contrast-enhanced Mean EOM-SV (mm3) SD/mean (%) 2 SD (%)
Average 76–261 130 3 4.9
MR, medial rectus; IR, inferior rectus; LR, lateral rectus; SRC, superior rectus complex; EOM-SV, extraocular muscle sampled volume.
Table 3. Intraclass correlation (ICC) of the measurements performed by the three operators.
Imaging condition ICC 1–2 ICC 1–3 ICC 2–3 ICC 1–2–3
Non-contrast-enhanced 0.995 0.995 0.995 0.997
Contrast-enhanced 0.996 0.996 0.997 0.998
ICC outcome values: 0¼ no agreement; 1¼ perfect agreement between measurements.
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currently no agreement in the literature on the cut-off
values to be used (14–21). On the other hand, a tendency
of the EOM-SV to expand would enable early diagnosis
of pathological enlargement, even if the value did not
reach a predefined cut-off.
There is no consensus on how to measure EOM
volume. The method described herein overcomes the dis-
advantages of current approaches, where a change of 6–
17% is required to reach significance in patients with
thyroid-associated ophthalmopathy (22–24). In fact,
these approaches alternate measurements between the
coronal and the axial plane and manual and semi-auto-
matic outlining and are hampered by the difficulty of seg-
menting the muscles at the tendon insertion (16,25,26).
Notably, the EOM-SV can be calculated exclusively on
coronal images, which are least affected by the partial
volume and curved shape of the EOM (11, 6). In addition,
the segmentation of the central portion of the muscles
excluded the influence of the tendon insertions. Use of
the polygon selection tool facilitated EOM segmentation,
where themarkedly enlargedmuscles were virtually indis-
tinguishable from one another. Segmentation and meas-
urement of an orbit (4 EOM-SV) took approximately
8min, which is consistent with routine clinical use, and
did not require special training.
High-field strength imaging with IDEAL sequences
helped EOM volume segmentation using an anisotropic
technique. The use of 3-T MRI increases the difference
in the chemical shift between water and fat. The IDEAL
technique uses three asymmetric echoes to calculate a
field map. The signal provides IDEAL water and
IDEAL fat, highlighting how water and fatty acids con-
tribute to the resonance signal. While the anisotropic
sequences and parallel-imaging techniques keep the
signal-to-noise ratio high, resulting in a shorter scanning
time (27). The examination of axial T1W and T2W
IDEAL water and fat images allowed for the depiction
of all infra-orbital structures in the prefascial and retro-
fascial spaces, which consist of loose cellular intraconal
and extraconal tissue (28). In addition, the non-contrast
T1W IDEAL fat sequences made it possible to discrim-
inate the hypointense signal of the maxillary sinus from
the hypointense EOM signal.
This study found that non-enhanced and contrast-
enhanced sequences are both suitable to assess the
EOM-SV. Furthermore, both sequence types effectively
depict the acute active and chronic inactive phases of
GO by identifying EOM fatty degeneration and scarring
(29–33). Orbital ultrasound (US) and computed tomog-
raphy (CT) can be employed to assess disease activity
and severity. However, US provides suboptimal EOM
measurement and poor visualization of the orbital apex,
while radiation exposure and a lack of correlation with
disease activity make CT not ideally suited in the follow-
up of GO patients (34). Altogether, we feel that MRI is
the most informative imaging technique to assess and
monitor these patients. The non-contrast sequences
allow both qualitative and quantitative follow-up, avoid-
ing the toxicity and cost of gadolinium and providing
comprehensive information for clinical decision-making,
whereas the contrast-enhanced sequences provide for
optimal staging of EOM scarring and differentiate GO
from other infra-orbital lesions (35).
Our study is preliminary and as such has several
limitations. First is the small sample size. A study
with a larger sample is needed to confirm the role of
the EOM-SV as a dimensional parameter of EOM
enlargement in GO patients. Second, these patients
may show a wide spectrum of orbital soft tissue
volume changes ranging from pure muscle to pure fat
(36). We could not establish whether EOM-SV size
changes correlate with proptosis severity in patients
with predominantly retro-orbital fat tissue involvement
because there were none in our sample; measuring
retro-orbital fat volume may be the best option in
such patients. In addition, this study is retrospective.
Moreover, other sources of error besides observer error
may be present, such as the error related to the ana-
tomical changes due to muscle contraction and the
error inherent to the partial volume effects. Further
work is required to achieve an accurate distinction
between the volume changes due to disease or treat-
ment and those related to technical issues.
In conclusion, 3-TMRI IDEALanisotropic sequences
provide both non-contrast and contrast-enhanced meas-
urement of the EOM-SV. In GO patients, EOM-SV can
be used to assess EOM enlargement and is more predict-
ive of proptosis than EOM-CSA. Its measurement is
reproducible, and changes of 3.5–8.3% can be assumed
to be true volume changes.
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